Favipiravir-resistant influenza A virus shows potential for transmission.
Favipiravir is a nucleoside analogue which has been licensed to treat influenza in the event of a new pandemic. We previously described a favipiravir resistant influenza A virus generated by in vitro passage in presence of drug with two mutations: K229R in PB1, which conferred resistance at a cost t...
Saved in:
| Main Authors: | Daniel H Goldhill, Ada Yan, Rebecca Frise, Jie Zhou, Jennifer Shelley, Ana Gallego Cortés, Shahjahan Miah, Omolola Akinbami, Monica Galiano, Maria Zambon, Angie Lackenby, Wendy S Barclay |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2021-06-01
|
| Series: | PLoS Pathogens |
| Online Access: | https://journals.plos.org/plospathogens/article/file?id=10.1371/journal.ppat.1008937&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The effect of favipiravir on fracture healing
by: Mehmet Ali Sabır, et al.
Published: (2024-05-01) -
Pharmacokinetic Interaction of Favipiravir with Citalopram and Pioglitazone
by: Zeliha Keskin Alkaç, et al.
Published: (2022-12-01) -
Transmission of a 2009 H1N1 pandemic influenza virus occurs before fever is detected, in the ferret model.
by: Kim L Roberts, et al.
Published: (2012-01-01) -
Quantitative Analysis of Favipiravir by HPLC: Development and Validation
by: Moammal Qurt, et al.
Published: (2023-01-01) -
Pharmacogenetic Markers of Favipiravir Safety in COVID-19 Treatment
by: I. I. Temirbulatov, et al.
Published: (2023-10-01)